UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 6, 2016
CymaBay Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 001-36500 | 94-3103561 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
7999 Gateway Blvd., Suite 130
Newark, CA 94560
(Address of principal executive offices)
(510) 293-8800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 6, 2016, the CymaBay Therapeutics, Inc. Board of Directors (the “Board”) appointed Robert Booth, Ph.D. and Caroline Loewy as members of the Board. Further, Dr. Booth was appointed as a member of the Compensation Committee and Ms. Loewy was appointed as a member of the Audit Committee. Dr. Booth and Ms. Loewy will each serve until CymaBay’s 2017 Annual Meeting of Stockholders or until his or her earlier death, resignation or removal and will be entitled to receive compensation as a non-employee director of CymaBay under CymaBay’s currently effective non-employee director compensation policy, which was filed as Exhibit 10.20 to CymaBay’s Annual Report on Form 10-K on March 23, 2015.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CymaBay Therapeutics, Inc. | ||
| By: |
/s/ Sujal Shah | |
|
| ||
| Name: |
Sujal Shah | |
| Title: |
Chief Financial Officer | |
Dated: December 8, 2016